Revel Pharmaceuticals

Revel Pharmaceuticals is a biotechnology commercializing therapeutic enzymes to degrade age associated molecule damage.

Founded 2019

San Francisco, United States 7 employees Seed Total: $8.40M Biotechnology, Life Sciences +1

Revel Pharmaceuticals is a biotechnology startup headquartered in the United States. Established in 2019, the company focuses on commercializing therapeutic enzymes to degrade age-associated molecule damage, particularly targeting Advanced Glycation End Products (AGEs). These compounds accumulate on long-lived proteins like collagen and are implicated in various age-related diseases. Recently, Revel Pharmaceuticals secured an impressive $8.40M in a Seed Round investment dated 17th March 2022, with prominent investors including Kizoo Technology Capital, Starbloom Capital, and Tubus. Revel Pharmaceuticals' mission aligns with the growing demand for innovative solutions in the pharmaceutical industry, especially those addressing aging-related health issues. The recent substantial investment signifies noteworthy confidence from key players in the venture capital arena, underscoring the potential of Revel Pharmaceuticals' approach in targeting age-associated molecule damage. This infusion of funds positions the company strategically to further develop therapeutics across multiple indications, potentially making significant strides in combating age-related diseases and enhancing overall human health. As a venture capital professional, these crucial developments at Revel Pharmaceuticals are indicative of the company's potential for disrupting the biotechnology and pharmaceutical sectors. The substantial Seed Round investment and the backing of reputable investors solidify Revel Pharmaceuticals' standing as a promising player in the biotech landscape. The company's focus on addressing age-related molecule damage through therapeutic enzymes presents an opportunity for substantial impact and innovation in the field of aging-related healthcare.

Funding Stage	Amount	Investors	Lead Investors	Date
Seed Round	$8.40M	3	Kizoo Technology Capital, Starbloom Capital +1	17 Mar 2022

Funding Stage

Amount

Investors

Lead Investors

Date

Seed Round

$8.40M

Kizoo Technology Capital, Starbloom Capital +1

17 Mar 2022

FAQ About Revel Pharmaceuticals

Revel Pharmaceuticals is a biotechnology commercializing therapeutic enzymes to degrade age associated molecule damage.

Revel Pharmaceuticals was founded in 2019.

Revel Pharmaceuticals is headquartered in San Francisco, United States.

Revel Pharmaceuticals operates in Biotechnology, Life Sciences and Pharmaceutical. Its work centres on therapeutic enzymes, AGEs, advanced glycation end products and diseases of aging.

Revel Pharmaceuticals has approximately 7 employees.

Revel Pharmaceuticals has completed 1 funding round, raising a total of $8.40M. The latest funding stage is Seed.

Top alternatives and competitors to Revel Pharmaceuticals include Lento Bio, Elixir Pharmaceuticals, Amplifier Therapeutics, Rejuvenate Bio, Opterion Health AG. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Revel Pharmaceuticals and Lento Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Revel Pharmaceuticals

Funding Rounds & Investors (1)

Revel Pharmaceuticals Alternatives & Competitors

FAQ About Revel Pharmaceuticals